"SILVER SPRING, MD â€” The US Food and Drug Administration (FDA) is warning of several treatment-related serious adverse events in association with implantable left ventricular assist devices (LVADs) in heart-failure patients.
In a "...
BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies].
DOSAGE AND ADMINISTRATION
In the management of ACS, initiate BRILINTA treatment with a 180 mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily.
Do not administer BRILINTA with another oral P2Y12 platelet inhibitor.
Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg [see WARNINGS AND PRECAUTIONS and Clinical Studies]. A patient who misses a dose of BRILINTA should take one tablet (their next dose) at its scheduled time.
For patients who are unable to swallow tablets whole, BRILINTA tablets can be crushed, mixed with water and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater) [see CLINICAL PHARMACOLOGY].
Dosage Forms And Strengths
BRILINTA (ticagrelor) 90 mg is supplied as a round, biconvex, yellow, film-coated tablet marked with a “90” above “T” on one side.
BRILINTA (ticagrelor) 60 mg is supplied as a round, biconvex, pink, film-coated tablet marked with “60” above “T” on one side.
BRILINTA (ticagrelor) 90 mg is supplied as a round, biconvex, yellow, film-coated tablet with a “90” above “T” on one side:
Bottles of 14 – NDC 0186-0777-28
Bottles of 60 – NDC 0186-0777-60
100 count Hospital Unit Dose – NDC 0186-0777-39
BRILINTA (ticagrelor) 60 mg is supplied as a round, biconvex, pink, film-coated tablet with a “60” above “T” on one side;
Bottles of 60 – NDC 0186-0776-60
Blister of 14 – NDC 0186-0776-94
Storage And Handling
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature].
Distributed by: AstraZeneca LP, Wilmington, DE 19850. Revised: Sep 2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/18/2015
Additional Brilinta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.